Interleukin 15 - Admune Therapeutics

Drug Profile

Interleukin 15 - Admune Therapeutics

Alternative Names: Heterodimeric IL-15; Heterodimeric Interleukin 15; hetIL-15; IL 15; NIZ985; sIL 15Ra

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Admune Therapeutics
  • Developer National Cancer Institute (USA); Novartis
  • Class Adjuvants; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC)
  • 24 Jun 2018 Biomarkers information updated
  • 21 Oct 2015 Admune Therapeutics has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top